Webinars, Pharmaceutical

Nose to Brain Drug Delivery – A Promising Future

Nose to brain drug delivery has considerable potential to address currently unmet needs for CNS therapeutics for the treatment of disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis.

This webinar discusses the mechanisms of drug delivery to the CNS, drug delivery technology considerations, and formulation ingredients and strategies, including an examination of the pros and cons of liquid vs. powder formulation. By bypassing the blood brain barrier, nose to brain drug delivery offers potential to deliver different drugs and lower doses with minimal systemic effect. The criticality of successful targeting of the olfactory region is noted and the beneficial role of excipients such as mucoadhesives and penetration enhancers is outlined.

Aptar Pharma’s expertise in all aspects of the development and reformulation of drugs for nose to brain delivery is highlighted.

Watch the webinar
Speaker(s): Reenal Gandhi Gemma Budd
22 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

26 Feb 2024

Intranasal Delivery of Monoclonal Antibodies via Dry Powder

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
2 Feb 2024

Systemic Nasal Drug Delivery for CNS Diseases and Beyond

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
30 Jan 2024

Nanoparticle Formulation Strategies for Intranasal Drug Delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
3 Jan 2024

Feasibility of Intranasal Delivery of Thin-Film Freeze-Dried Monoclonal Antibodies

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 2 3 4 5 6 27

Request Access

Close

Requesting access to Nose to Brain Drug Delivery – A Promising Future.

  • This field is for validation purposes and should be left unchanged.
Back To Top